Inactive Instrument
Cerevel Therapeutics Holdings, Inc. Stock
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
| 1 day | +0.74% |
| 3 years | 21.86 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/05/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 20/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 20/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 01/08/24 | Issuer sale | Director | 108,985 | 0.0598% | ||
| 01/08/24 | Issuer sale | Director | 137,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | - | - | 8.19B | |
| +0.79% | -6.16% | +49.32% | +74.50% | 66.34B | |
| -0.77% | +5.81% | +10.92% | +89.07% | 52.92B | |
| -0.15% | +4.72% | +7.34% | +73.30% | 54.82B | |
| -0.12% | +2.75% | +26.31% | +45.29% | 44.09B | |
| -0.35% | +10.15% | +20.69% | +132.73% | 43.72B | |
| +1.31% | +4.30% | +263.91% | +602.72% | 42.13B | |
| -0.40% | +9.85% | +17.04% | +59.17% | 33.96B | |
| -1.30% | -0.68% | +37.15% | +7.04% | 26.17B | |
| -0.15% | +4.59% | +35.30% | +25.18% | 23.37B | |
| Average | +0.08% | +4.96% | +52.00% | +123.22% | 43.06B | |
| Weighted average by Cap. | +0.10% | +4.85% | +51.12% | +128.12% |
Employees
355
